CA2908240A1 - Blocking of cue-induced drug reinstatement - Google Patents

Blocking of cue-induced drug reinstatement Download PDF

Info

Publication number
CA2908240A1
CA2908240A1 CA2908240A CA2908240A CA2908240A1 CA 2908240 A1 CA2908240 A1 CA 2908240A1 CA 2908240 A CA2908240 A CA 2908240A CA 2908240 A CA2908240 A CA 2908240A CA 2908240 A1 CA2908240 A1 CA 2908240A1
Authority
CA
Canada
Prior art keywords
ethoxycarbonyl
drug
laurate
acetate
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2908240A
Other languages
English (en)
French (fr)
Inventor
Stanley D. Glick
James E. Polston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albany Medical Center Hospital
Original Assignee
Albany Medical Center Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Medical Center Hospital filed Critical Albany Medical Center Hospital
Publication of CA2908240A1 publication Critical patent/CA2908240A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2908240A 2012-03-27 2013-03-25 Blocking of cue-induced drug reinstatement Abandoned CA2908240A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615953P 2012-03-27 2012-03-27
US61/615,953 2012-03-27
PCT/US2013/033703 WO2013148572A1 (en) 2012-03-27 2013-03-25 Blocking of cue-induced drug reinstatement

Publications (1)

Publication Number Publication Date
CA2908240A1 true CA2908240A1 (en) 2013-10-03

Family

ID=49261147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2908240A Abandoned CA2908240A1 (en) 2012-03-27 2013-03-25 Blocking of cue-induced drug reinstatement

Country Status (6)

Country Link
US (1) US20150051192A1 (enExample)
EP (1) EP2830601A4 (enExample)
JP (1) JP2015522522A (enExample)
AU (1) AU2013239995A1 (enExample)
CA (1) CA2908240A1 (enExample)
WO (1) WO2013148572A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CA2806232A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
EP2934541A4 (en) * 2012-12-20 2016-08-03 Demerx Inc SUBSTITUTED NORIBOGAIN
US20150258110A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence using ibogaine
EP3164402A1 (en) * 2014-04-21 2017-05-10 DemeRx, Inc. N-substituted noribogaine prodrugs
WO2021067549A1 (en) * 2019-10-01 2021-04-08 Mind Medicine, Inc. 18-mc for treatment of substance use disorders
US20220409628A1 (en) * 2021-06-29 2022-12-29 Mind Medicine, Inc. 18-mc for treating obesity
WO2025117491A1 (en) * 2023-12-01 2025-06-05 Kuleon Llc Azepino analogs and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005869A1 (en) * 1995-08-08 1997-02-20 Albany Medical College Ibogamine congeners
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
EP1776121A2 (en) * 2004-08-13 2007-04-25 Omeros Corporation Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
JP2010505960A (ja) * 2006-10-09 2010-02-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ニコチン禁断症状および／またはタバコ使用の軽減用組成物
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
MX2011009384A (es) * 2009-03-11 2011-10-11 Omeros Corp Composiciones y metodos para profilaxis y tratamiento de adicciones.
US8785472B2 (en) * 2010-05-11 2014-07-22 National Cheng Kung University Use of dextromethorphan in treating addictive behavior or bipolar disorder

Also Published As

Publication number Publication date
US20150051192A1 (en) 2015-02-19
EP2830601A4 (en) 2015-09-23
WO2013148572A1 (en) 2013-10-03
JP2015522522A (ja) 2015-08-06
EP2830601A1 (en) 2015-02-04
AU2013239995A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
US20150051192A1 (en) Blocking of cue-induced drug reinstatement
Dodd et al. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Stefanski et al. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine
Park et al. Cocaine administered into the medial prefrontal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens
Villégier et al. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine
Zlebnik et al. Effects of combined exercise and progesterone treatments on cocaine seeking in male and female rats
Popik et al. Mesolimbic NMDA receptors are implicated in the expression of conditioned morphine reward
Eisenberg et al. The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats
Liu et al. Effects of dopamine antagonists on drug cue-induced reinstatement of nicotine-seeking behavior in rats
Wong et al. Poisoning with illicit substances: toxicology for the anaesthetist
Voigt et al. Context-dependent effects of a single administration of mirtazapine on the expression of methamphetamine-induced conditioned place preference
Di Pietro et al. Role of dopamine D1 receptors in the prefrontal dorsal agranular insular cortex in mediating cocaine self-administration in rats
Steinmiller et al. Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine
West et al. A selective test for antidepressant treatments using rats bred for stress-induced reduction of motor activity in the swim test
US20110039834A1 (en) Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions
Lan et al. Enhancing effects of morphine on methamphetamine‐induced reinforcing behavior and its association with dopamine release and metabolism in mice
Li et al. The Cdk5 inhibitor β‐butyrolactone impairs reconsolidation of heroin‐associated memory in the rat basolateral amygdala
Jang et al. Attenuation of morphine tolerance and withdrawal syndrome by coadministration of nalbuphine
Mitchem et al. The effects of the naltrexone implant on rodent social interactions and cocaine-induced conditioned place preference
Yang et al. Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization
Sadri‐Vakili et al. Inhibition of NMDA‐induced striatal dopamine release and behavioral activation by the neuroactive steroid 3α‐hydroxy‐5β‐pregnan‐20‐one hemisuccinate
Polston et al. 18-Methoxycoronaridine blocks context-induced reinstatement following cocaine self-administration in rats
Villégier et al. Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self‐administration
Fox et al. A role for 5-HT2C receptor antagonists in the treatment of Parkinson
Butler¹ et al. Impact of Substance Use Disorder Pharmacotherapy on Executive

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20190326